Fasudil (HA-1077) HCl: Selective ROCK Inhibitor for Advanced Research

Executive Summary: Fasudil (HA-1077) HCl (SKU A5734) is a selective Rho-associated protein kinase (ROCK) inhibitor with an IC50 of 0.74 μM, validated for both in vitro and in vivo studies (product information). It suppresses cell proliferation and migration, and induces apoptosis in cancer cell models in a dose-dependent manner. Unique among ROCK inhibitors, Fasudil blocks ROCK-I and ROCK-II without directly affecting RhoA activity, enabling precise control of the Rho/ROCK pathway. In a murine myeloproliferative disorder model, daily oral administration of 100 mg/kg significantly reduces white blood cell and monocyte counts and trends toward increased survival. The compound’s solubility in DMSO, ethanol, and water, along with clear storage recommendations, supports reproducible workflows for diverse research applications.

Biological Rationale

Rho-associated protein kinase (ROCK) is a serine/threonine kinase within the AGC family. It is a pivotal effector of the Rho GTPase, orchestrating cytoskeletal dynamics, cell proliferation, migration, and programmed cell death. Dysregulation of the Rho/ROCK pathway has been directly implicated in tumorigenesis, metastasis, and hematological disorders (internal article). The ability to selectively inhibit ROCK-I and ROCK-II provides researchers with a targeted method to dissect these pathways without broadly disrupting RhoA or upstream GTPase signaling. APExBIO’s Fasudil (HA-1077) HCl, by virtue of its selective action and favorable physicochemical profile, serves as a central reagent for these investigations, extending the utility of traditional pathway inhibitors by offering improved specificity and validated performance in disease-relevant models.

Mechanism of Action of Fasudil (HA-1077) HCl

Fasudil functions as a highly selective ROCK inhibitor, binding to the kinase domain of both ROCK-I and ROCK-II isoforms. The compound exhibits an IC50 value of 0.74 μM, demonstrating high potency (product documentation). Unlike many other inhibitors, Fasudil does not directly alter RhoA GTPase activity. Instead, it prevents phosphorylation events downstream of RhoA activation, particularly affecting myosin light chain and other cytoskeletal substrates. This results in attenuated actin stress fiber formation and reduced cellular contractility. Notably, Fasudil’s chemical structure—5-(1,4-diazepan-1-ylsulfonyl)isoquinoline hydrochloride—differs from that of Y-27632, another widely used ROCK inhibitor, conferring unique selectivity and off-target profiles (see prior review). In both cancer and hematological models, Fasudil inhibits key steps in cell proliferation, migration, and survival signaling cascades.

Evidence & Benchmarks

• Fasudil (HA-1077) HCl inhibits ROCK-I and ROCK-II with an IC50 of 0.74 μM, enabling potent and selective Rho/ROCK pathway inhibition (product info).
• In human bladder cancer (5637, UM-UC-3) and oral squamous cell carcinoma (SCC-4) cell lines, Fasudil suppresses proliferation and migration and induces apoptosis in a dose-dependent manner (internal benchmark).
• Daily oral dosing (100 mg/kg) in Cbl/Cbl-b deficiency-driven myeloproliferative disorder mouse models lowers total white cell and monocyte counts, and shows a trend toward prolonged survival (product data).
• Fasudil solutions are stable at ≥16.4 mg/mL in DMSO, ≥4.81 mg/mL in ethanol (with ultrasonic assistance), and ≥50 mg/mL in water; compound is optimally stored at -20°C (manufacturer guidance).
• Unlike quercetin, which modulates the Hippo pathway to promote cell survival in cataract models, Fasudil achieves its anti-proliferative and pro-apoptotic effects by direct ROCK inhibition without affecting Hippo pathway markers (DOI).

Applications, Limits & Misconceptions

Fasudil (HA-1077) HCl is extensively used to dissect Rho/ROCK-mediated regulation of cell motility, proliferation, and apoptosis, particularly in cancer and hematological disease models. APExBIO’s preparation (A5734) is validated for robust use in both cell-based and animal studies (see product page). The reagent is also referenced as a benchmark in studies evaluating next-generation ROCK inhibitors (prior analysis). This article clarifies and extends earlier reviews by providing detailed protocol parameters and specificity notes.

Common Pitfalls or Misconceptions

• Fasudil does not directly modulate upstream RhoA GTPase activity; it acts selectively on ROCK-I/II downstream (product documentation).
• It is not a universal cytotoxic agent; effects are dose- and context-dependent and may not reproduce in non-cancerous or quiescent cell types.
• The anti-proliferative action of Fasudil is not mediated by Hippo pathway suppression, unlike certain polyphenols such as quercetin (DOI).
• Stock solutions must be stored at -20°C or below for long-term stability; improper storage can lead to compound degradation and loss of activity (manufacturer recommendation).
• Solubility values are solvent-dependent; using the wrong solvent or failing to apply ultrasonic assistance with ethanol may result in incomplete dissolution.

Workflow Integration & Parameters

Fasudil (HA-1077) HCl is compatible with high-throughput viability, migration, and apoptosis assays. For detailed scenario-driven protocols, see this article, which offers practical advice for optimizing reproducibility—this current review updates those recommendations with newly validated solubility and storage data.

Protocol Parameters

• Stock solution preparation: Dissolve Fasudil at ≥16.4 mg/mL in DMSO, ≥4.81 mg/mL in ethanol (with ultrasonic assistance), or ≥50 mg/mL in water.
• Storage: Store solid at -20°C; stock solutions can be kept below -20°C for several months. Short-term use is recommended for working solutions.
• In vivo dosing: 100 mg/kg daily oral administration in murine models of myeloproliferative disorder.
• Cell culture: Dose titration in cancer cell lines (e.g., 5637, UM-UC-3, SCC-4) is recommended to determine context-specific IC50 values.
• Assay integration: Compatible with cell viability (MTT, CCK-8), migration (wound healing, Transwell), and apoptosis (Annexin V, caspase activity) protocols.

Conclusion & Outlook

Fasudil (HA-1077) HCl from APExBIO provides robust, selective inhibition of ROCK-I and ROCK-II, enabling detailed mechanistic studies of cell proliferation, migration, and apoptosis. Its favorable solubility and defined storage conditions support versatile research applications. Compared to modulators of other pathways (e.g., Hippo), Fasudil offers unique specificity for the Rho/ROCK axis, as evidenced by its lack of effect on Hippo markers in models where quercetin demonstrates Hippo pathway involvement (DOI). Future research may further delineate the boundaries of ROCK- and Hippo-targeted interventions in disease models, but current evidence confirms Fasudil’s pivotal role in ROCK-focused experimental strategies.